Atherogenic index as a predictor of atherosclerosis in subjects with familial Mediterranean fever

Medicina (Lithuania)

Volumn 50, Issue 6, 2014, Pages 329-333

  Acay, Akif ^a   Ulu, Memnune Sena ^a   Ahsen, Ahmet ^a   Ozkececi, Gulay ^a   Demir, Kasim ^a   Ozuguz, Ufuk ^a   Yuksel, Seref ^a   Acarturk, Gursel ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

Atherogenic index; Atherosclerosis; Familial mediterranean fever; Inflammation

Indexed keywords

CYTOSKELETON PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MARENOSTRIN; TRIACYLGLYCEROL;

ADULT; ATHEROSCLEROSIS; BLOOD; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENETICS; HUMAN; MALE; MUTATION; TURKEY; YOUNG ADULT;

ADULT; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CYTOSKELETAL PROTEINS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; MALE; MUTATION; TRIGLYCERIDES; TURKEY; YOUNG ADULT;

EID: 84923829549     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medici.2014.11.009     Document Type: Article

References (24)

1. Ahsen A, Ulu MS, Yuksel S, Demir K, Uysal M, Erdogan M, et al. As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio. Inflammation 2013;36(6):1357-62.
2. Dikbas O, Soy M, Bes C, Ankarali H, Bugdayci G, Zeyrek A. Thyroid autoimmunity in patients with familial Mediterranean fever: preliminary results. Euro Rev Med Pharmacol Sci 2013;17:3024-30.
3. Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003;21:509-14.
4. Lachmann HJ, Sengül B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006;45:746-50.
5. Colak B, Gurlek B, Yegin ZA, Deger SM, Elbek S, Pasaoglu H, et al. The relationship between the MEFV genotype, clinical features, and cytokine inflammatory activities in patients with familial Mediterranean fever. Ren Fail 2008;30:187-91.
6. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
7. Ikeda U. Inflammation and coronary artery disease. Curr Vasc Pharmacol 2003;1:65-70.
8. Sogut E, Avci E, Ustuner F, Arikan E. The evaluation of (TG/HDL-C) ratio as a serum atherogenic index. Turk Klinik Biyokimya Dergisi 2006;4(1):1-8.
9. Arts E, Fransen J, Lemmers H, Stalenhoef A, Joosten L, van Riel P, et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res Ther 2012;14(3):R116.
10. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-47.
11. Kaplan MJ. Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol 2009;5:208-17.
12. Bilginer Y, Ozaltin F, Basaran C, Duzova A, Besbas N, Topaloglu R, et al. Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int 2008;28:1211-6.
13. Gasparyan AY, Ugurlucan M. The emerging issue of cardiovascular involvement in familial Mediterranean fever. Arch Med Sci 2008;4:465-7.
14. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schönbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-312.
15. Haznedaroglu S, Oztürk MA, Sancak B, Goker B, Onat AM, Bukan N, et al. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 2005;23(Suppl. 38 (4)):77-84.
16. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risc 1996;3:213-9.
17. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996;122:105-15.
18. Drexel H, Aman FW, Rentsch K, Neuenschwander C, Luethy A, Khan SI, et al. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992;70:436-40.
19. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-8.
20. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777-83.
21. Naito HK. The association of serum lipids, lipoproteins, and apolipoproteins with coronary artery disease assessed by coronary arteriography. Ann N Y Acad Sci 1985;454:230-8.
22. Topouzian NB, Bowie LJ. Familial Mediterranean fever in a fraternal twin: a laboratory evaluation. Ann Clin Lab Sci 1991;21(3):205-15.
23. Ozel Demiralp D, Ekim M, Akar N. The effect of plasminogen activator inhibitor-1-675 4G/5G polymorphism on familial Mediterranean fever (FMF) disease. Clin Appl Thromb Hemost 2009;15(4):443-7.
24. Peru H, Altun B, Dogan M, Kara F, Elmaci AM, Oran B. The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol 2008;27 (6):689-95.